Phio Pharmaceuticals announced on December 19, 2024, that its Phase 1b clinical trial for PH-762 received approval from the Safety Monitoring Committee to proceed to the third dose cohort. The trial evaluates PH-762's safety and tolerability in treating various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.Initial efficacy data from the second cohort, comprising 4 patients with cutaneous squamous cell carcinoma, showed promising results. The first two patients who completed treatment demonstrated a complete response (100% tumor clearance) and partial response (90% clearance) at Day 36, with pathology data pending for the remaining patients. Importantly, the intratumoral injections were well-tolerated with no dose-limiting toxicities or serious adverse events reported.PH-762, utilizing Phio's proprietary INTASYL siRNA gene silencing technology, targets PD-1 and is being developed as a non-surgical treatment for skin cancers. The trial, which received FDA clearance in Q2 2023, represents a significant step in advancing the company's immuno-oncology therapeutic platform.

Phio Pharmaceuticals announced on December 19, 2024, that its Phase 1b clinical trial for PH-762 received approval from the Safety Monitoring Committee to proceed to the third dose cohort. The trial evaluates PH-762's safety and tolerability in treating various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.Initial efficacy data from the second cohort, comprising 4 patients with cutaneous squamous cell carcinoma, showed promising results. The first two patients who completed treatment demonstrated a complete response (100% tumor clearance) and partial response (90% clearance) at Day 36, with pathology data pending for the remaining patients. Importantly, the intratumoral injections were well-tolerated with no dose-limiting toxicities or serious adverse events reported.PH-762, utilizing Phio's proprietary INTASYL siRNA gene silencing technology, targets PD-1 and is being developed as a non-surgical treatment for skin cancers. The trial, which received FDA clearance in Q2 2023, represents a significant step in advancing the company's immuno-oncology therapeutic platform.